GT Biopharma has filed a notice of an exempt offering of securities to raise $38,958,054.00 in New Funding.
According to filings with the U.S. Securities and Exchange Commission, GT Biopharma is raising up to $38,958,054.00 in new funding. The federal securities law requires the notice to be filed by...
According to filings with the U.S. Securities and Exchange Commission, GT Biopharma is raising up to $38,958,054.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About GT Biopharma
GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical-stage immuno-oncology company focused on developing innovative cancer therapies. Its proprietary TriKE platform produces targeted immunotherapeutic agents that simultaneously engage natural killer (NK) cells and cancer cells to promote selective cancer-cell killing. The company is developing novel immuno-oncology drugs for acute lymphocytic leukemia, non-Hodgkins lymphoma, acute myeloid leukemia, multiple myeloma, and several solid tumors. GT Biopharmas pipeline includes GTB-5550, a B7-H3-targeted NK cell engager with a potential application in multiple myeloma. The company regularly provides investor and scientific updates on the development of its TriKE platform and cancer-treatment programs.
To learn more, visit https://www.gtbiopharma.com/
LinkedIn: https://www.linkedin.com/company/gtbiopharma/
Contact:
Alan Urban, Chief Financial Officer
SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.



No Comment! Be the first one.